Optimizing PCSK9 Inhibitor Integration for Cardiovascular Disease Management in Pakistan.

IF 2.3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Clinical Medicine Insights. Cardiology Pub Date : 2024-06-19 eCollection Date: 2024-01-01 DOI:10.1177/11795468241262648

Muddassir Syed Saleem, Shahzaib Samad, Syed Shahmeer Ahmed, Nadia Mehmood

{"title":"Optimizing PCSK9 Inhibitor Integration for Cardiovascular Disease Management in Pakistan.","authors":"Muddassir Syed Saleem, Shahzaib Samad, Syed Shahmeer Ahmed, Nadia Mehmood","doi":"10.1177/11795468241262648","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular illnesses (CVDs), particularly Coronary Artery Disease (CAD) and Ischemic Heart Disease (IHD), are major global health burdens, with a growing incidence in Pakistan. The development of PCSK9 inhibitors offers encouraging advantages in lowering LDL cholesterol and lowering cardiovascular risk, even though conservative treatments are still essential. However, access to them is severely hampered by their high cost, especially in environments with little resources. The financial limitations and scarcity of healthcare resources while examining the difficulties in obtaining PCSK9 inhibitors in Pakistan is essential. In order to develop solutions for affordability and fair access, it emphasizes the urgent need for multi-stakeholder collaboration, including governmental action, healthcare sector involvement, and pharmaceutical company engagement. It also emphasizes the need for data-specific research and the use of PCSK9 inhibitors in conventional treatment protocols.</p>","PeriodicalId":10419,"journal":{"name":"Clinical Medicine Insights. Cardiology","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191606/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795468241262648","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Cardiovascular illnesses (CVDs), particularly Coronary Artery Disease (CAD) and Ischemic Heart Disease (IHD), are major global health burdens, with a growing incidence in Pakistan. The development of PCSK9 inhibitors offers encouraging advantages in lowering LDL cholesterol and lowering cardiovascular risk, even though conservative treatments are still essential. However, access to them is severely hampered by their high cost, especially in environments with little resources. The financial limitations and scarcity of healthcare resources while examining the difficulties in obtaining PCSK9 inhibitors in Pakistan is essential. In order to develop solutions for affordability and fair access, it emphasizes the urgent need for multi-stakeholder collaboration, including governmental action, healthcare sector involvement, and pharmaceutical company engagement. It also emphasizes the need for data-specific research and the use of PCSK9 inhibitors in conventional treatment protocols.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在巴基斯坦优化 PCSK9 抑制剂在心血管疾病管理中的应用。

心血管疾病（CVD），尤其是冠状动脉疾病（CAD）和缺血性心脏病（IHD），是全球主要的健康负担，在巴基斯坦的发病率越来越高。PCSK9 抑制剂的开发在降低低密度脂蛋白胆固醇和降低心血管风险方面具有令人鼓舞的优势，尽管保守治疗仍然必不可少。然而，高昂的费用严重阻碍了这些药物的使用，尤其是在资源匮乏的环境中。在研究巴基斯坦难以获得 PCSK9 抑制剂的原因时，必须考虑到财政限制和医疗资源稀缺的问题。为了制定负担得起和公平获取的解决方案，报告强调迫切需要多方利益相关者的合作，包括政府行动、医疗保健部门的参与和制药公司的参与。报告还强调需要开展针对特定数据的研究，并在常规治疗方案中使用 PCSK9 抑制剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊